Testing process
OwnerEugene Pergament, Carol J. Wilson +2inventors
InventorsEugene Pergament, Carol J. Wilson, Philip Wyatt, Howard S. Cuckle
Life of this patent
Estimating the term…
Abstract
A method of determining an inclusive residual risk that a pregnancy is affected by at least one phenotypic disorder included in a disorder set is provided. The method includes calculating a prior risk for a disorder set, calculating posterior risks for the individual disorders or groups of disorders in the disorder set that can be screened for and/or diagnosed prenatally, and calculating an inclusive residual risk for the disorder set by combining the prior risks for disorders for which no tests have been performed and the individual posterior risks.
Claims27
A method of estimating an inclusive residual risk, being a measure of the posterior probability that a pregnancy is affected by at least one phenotypic disorder included in a pre-selected disorder set, the said method comprising the steps of:
- a) determining an appropriate scheduled prenatal test or tests for any specific disorders or groups of disorders within the disorder set that can be screened for and/or diagnosed prenatally;
- b) calculating a prior risk for the disorder set;
- c) calculating posterior risks for the specific disorders or groups of disorders in the disorder set that can be screened for and/or diagnosed prenatally, based on scheduled test results;
- and
- d) calculating an inclusive residual risk for the disorder set by combining the prior risks for disorders within the disorder set for which no scheduled tests have been performed and the posterior risks for the disorders or groups of disorders within the disorder set for which scheduled tests have been performed.
A multi-stage prenatal testing process comprising the steps of:
- a) determining an appropriate schedule of screening and/or diagnostic tests for any specific disorders or groups of disorders within a preselected disorder set that can be tested prenatally;
- the scheduled tests to include diagnostic testing if the inclusive residual risk or one or more individual risks for a disorder or group of disorders within the disorder set exceeds a high risk threshold following a scheduled screening test or tests;
- b) performing scheduled prenatal tests;
- c) calculating a modified inclusive residual risk of the pregnancy being affected by a disorder within a specified disorder set, and individual risks for disorders or groups of disorders in the disorder set, after each scheduled test in a stepwise risk refinement process;
- and
- d) calculating a final inclusive residual risk, taking into account all prior and testing information, after the testing process has terminated.
A method of determining an inclusive residual risk of a pregnancy being affected by any severe congenital anomaly, or subset of severe congenital anomaly, including a finding or non-finding of molecular lesions from expression arrays or Microarray-Based Comparative Genomic Hybridization (a-CGH), the said method comprising the steps of:
- a) calculating a prior risk for the pregnancy being affected by any severe congenital anomaly, or by any disorder in a disorder set of interest to the patient;
- b) modifying the prior risk by calculating a likelihood ratio for each disorder or group of disorders in the set for which there are known associations with molecular lesion locations, and applying the likelihood ratios to the prior risk to give a posterior risk;
- c) modifying the prior risk by estimating the proportion of prior risk for the disorder set that can be removed where a known proportion of a disorder or group of disorders is due to molecular lesions at specific locations, following normal findings at those locations, to give a posterior risk;
- d) modifying the prior risk for disorders or groups of disorders, or for all significant congenital anomalies, where whole-genome array results are available and where molecular lesions of uncertain specific significance are found, to give a posterior risk;
- and
- e) calculating the inclusive residual risk by combining the posterior risks for each disorder or group of disorders for which the finding or non-finding of molecular lesions provides information that can be used in risk modification, and the prior risks for each disorder or group of disorders for which it does not.
A final inclusive residual risk which provides a personalized risk of a pregnancy being affected by any disorder within a disorder set, taking into account information generated by any performed prenatal screening and/or diagnostic tests and prior risks for any disorders within the disorder set for which prenatal screening and/or diagnostic tests have or have not been performed.
A computer program product that when run is operable to perform a method of determining an inclusive residual risk of a pregnancy being affected by any phenotypic disorder included in a disorder set, the said method comprising the steps of:
- a) calculating a prior risk for the disorder set;
- b) calculating posterior risks for the specific disorders or groups of disorders in the disorder set that are screened for and/or diagnosed prenatally, based on scheduled test results;
- c) calculating an inclusive residual risk for the disorder set at each step of a multi-stage testing process by combining the posterior risks for the disorders or groups of disorders that have been tested and the prior risks for the disorders that have not been tested;
- and
- d) calculating a final inclusive residual risk for the disorder set after the testing process has terminated.
Dependencies are inferred from the claim text.